{"url":"https://lda.senate.gov/api/v1/filings/1fdfbfcf-bb2e-43dd-abd9-aa5b2811ce32/","filing_uuid":"1fdfbfcf-bb2e-43dd-abd9-aa5b2811ce32","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2016,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.senate.gov/filings/public/filing/1fdfbfcf-bb2e-43dd-abd9-aa5b2811ce32/print/","filing_document_content_type":"text/html","income":null,"expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Gary Heimberg","dt_posted":"2016-07-15T19:14:22.717000-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"850 10th Street, NW","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20001","registrant":{"id":11195,"url":"https://lda.senate.gov/api/v1/registrants/11195/","house_registrant_id":31827,"name":"COVINGTON & BURLING LLP","description":"Law firm","address_1":"850 10th Street, NW","address_2":null,"address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20001","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"NICHOLAS XENAKIS","contact_telephone":"+1 202-662-5846","dt_updated":"2026-07-29T10:42:26.460623-04:00"},"client":{"id":115253,"url":"https://lda.senate.gov/api/v1/clients/115253/","client_id":1005395,"name":"FABRE-KRAMER PHARMACEUTICALS, INC","general_description":"Pharmaceutical company","client_government_entity":false,"client_self_select":null,"state":"TX","state_display":"Texas","country":"US","country_display":"United States of America","ppb_state":"TX","ppb_state_display":"Texas","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2015-07-31"},"lobbying_activities":[{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"Policy regarding demonstration of effectiveness for new drug approvals.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":62928,"prefix":null,"prefix_display":null,"first_name":"GARY","nickname":null,"middle_name":null,"last_name":"HEIMBERG","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}